Abstract:Plasma rich in growth factors (PRGF) can be used over patients suffering from dermatoses due to its anti-inflammatory effect. However, this population group might present soluble autoimmune components and there is limited information about the effect of chronic skin inflammation on PRGF bioactive properties. With the aim of characterizing PRGF composition, PRGF from healthy (H) donors and patients with atopic dermatitis (AD), psoriasis (PS), or lichen sclerosus (LS) was obtained. In order to reduce the inflammatory component, leukocyte exclusion and heat-inactivation (Immunosafe) were tested. Haematological-serological parameters, platelet functionality, clot microstructure, protein content and bioactivity were determined. Mean values and 95% confidence intervals (mean[95% CI]) were computed for key haematological parameters, such as platelet (410×10 3 /mm 3 [371-449]) and leukocyte content (205×10 3 /mm 3 [148-262]), platelet activation (resting: 4.3%[3.1-5.5] and activated: 97.4%[96.7-98.0]), the concentration of plasma proteins and morphogens, including immunoglobulins A (210.7 mg/dL[191.8-229.6]), G (933.1 mg/dL[887.2-978.9]), E (783.5 mg/dL[54.4-1512.6]), and M (115.0 mg/dL[97.1-133.0]), Complement Protein (31.6 mg/mL[26.6-36.6]), C-Reactive protein (3.1 mg/L[2.0-4.1]), TGF-β1 (35975.6 pg/mL[34221.3-37729.8]), fibronectin (146410.0 ng/mL[136518.3-156301.7]), PDGF-AB (13308.5 pg/mL[12401.0-14216.0]), CD40L (2389.3 pg/mL[1887.7-2890.8]), IL-4 (0.12 pg/mL[0.07-0.18]), IL-13 (35.4 pg/mL[21.0-49.7]), IL-1β (0.09 pg/mL[0.06-0.11]) and TNF-α (0.31 pg/mL[0.24-0.38]), and also for cell proliferation (332.9ngDNA/mL[317.4-348.3]), viability (135.6%[132.0-139.2]) and migration (103.8cells/mm 2 [98.3-109.3]). Plasma from AD donors presented increased Immunoglobulin E (IgE) that was significantly reduced after Immunosafe along with the complement system and autoantibodies. Platelet functionality was altered for AD, but no microstructure differences were identified. Pathological groups presented reduced concentration of fibronectin (AD/LS) and Platelet-Derived Growth Factor (PDGF-AB) (P). Immunosafe treatment reduced Cluster of Differentiation 40 Protein (CD40L), interleukin 1β (IL-1β), and Tumor Necrosis Factor α (TNF-α) concentrations. Fibroblasts supplemented with PRGF obtained from pathological patients (PS/AD) showed reduced viability but Immunosafe increased cell proliferation and migration in SP (LS) and L-SP samples (PS/AD). In conclusion, PRGF derived from pathological patients present autoimmune components, but heat-inactivation or leukocyte exclusion could minimize local side effects.

Preparation of placenta factor and its immunoregulatory effects on lymphocytes in vitro]

[Preparation of Placental-Eluted Gamma Globulin and Its Immunosuppressive Effect in Vitro and in Vivo].

Biological Characterization of Human Amniotic Epithelial Cells in a Serum-Free System and Their Safety Evaluation.

Anti-placental Growth Factor Antibody Ameliorates Hyperoxia-Mediated Impairment of Lung Development in Neonatal Rats

Purification of Placenta-Eluted Gamma Globulins and Their Strong Effect against Graft-versus-Host Reactions In Vitro and In Vivo

The Effect of Trophoblasts on T Lymphocytes: Possible Regulatory Effector Molecules - A Proteomic Analysis

Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma

Influences of the 3rd Trimester Placental Factor on Mouse Lymphocytes Proliferation

A Novel Factor Produced by Placental Cells with Activity Against HIV-1.

Clinical effects of double filtration plasmapheresis for sensitized recipients of cadaver kidney transplantation

Protection against lung cancer patient plasma-induced lymphocyte suppression by Ganoderma lucidum polysaccharides

Protection Against Lung Cancer Patient Plasma-Induced Lymphocyte Suppression Byganoderma LucidumPolysaccharides

Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection

Placenta-Derived Mesenchymal Stem Cells Have an Immunomodulatory Effect That Can Control Acute Graft-Versus-Host Disease in Mice

EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITRO: I. Inhibition of Expression of Alloanticen‐Activated Suppressor Cells, As Well As Induction of Alloreactivity

Preparation of a novel monoclonal antibody against active components of PHA-L from Phaseolus vulgaris and its functional characteristics

Impact of inflammatory skin conditions on the biological profile of plasma rich in growth factor

Low-dose Post-Transplant Cyclophosphamide Can Mitigate GVHD and Enhance the G-CSF/ATG Induced GVHD Protective Activity and Improve Haploidentical Transplant Outcomes.

Inhibition of human lymphocyte reactivity by plasma fibronectin in vitro

Cellular immunosuppression effect of polysaccharides HGT-5A from Periploca forrestii Schlecht and its possible active components

Regulation of Immune Checkpoint Antigen CD276 (B7-H3) on Human Placenta-Derived Mesenchymal Stromal Cells in GMP-Compliant Cell Culture Media